Low testosterone: full hormonal evaluation and evidence-led treatment.

TRT delivers bioidentical testosterone via several routes, each with distinct advantages. Choice depends on patient preference, lifestyle, fertility plans, and medical history.

Topical gel (daily application): Applied to upper arms, shoulders or abdomen each morning. Produces stable physiological levels. Requires care to avoid transferring to partners or children through skin contact. Most flexible to stop if needed.

Intramuscular injection: Shorter-acting preparations given every 2-3 weeks. Longer-acting preparations given every 10-14 weeks after a loading phase. Some prefer the convenience; others dislike the cyclical highs and lows of the shorter formulations.

Effectiveness: Most patients experience meaningful symptom improvement within 8-12 weeks. Libido and mood often improve first; energy, muscle mass, and body composition changes follow over 3-6 months. It can take between 6-9 months to see improvement of erections in patients that have erectile dysfunction due to low testosterone levels.

Eligibility: TRT requires confirmed clinical hypogonadism - total testosterone below 12 nmol/L on two morning samples,² accompanied by symptoms. Contraindications include untreated prostate cancer, untreated severe sleep apnoea, severe heart failure, haematocrit above 50%, and active desire for fertility.

Side effects: Generally well-tolerated with monitoring. Possible effects include increased red blood cell count (managed by monitoring haematocrit), worsening of pre-existing sleep apnoea, acne, breast tenderness, and reduced fertility. PSA elevation is monitored to detect any prostate change early.

In secondary (central) hypogonadism the testes are capable of producing testosterone, but the signal from the pituitary is suppressed. Where that suppression has an identifiable and reversible cause, treating the cause comes first.

Separating primary from secondary: the LH and FSH pattern alongside total and free testosterone tells us whether the problem sits in the testes or in the central signal. Prolactin, thyroid function, HbA1c, and a full blood count are checked in the same workup, with pituitary imaging arranged when the picture warrants it.

Common reversible drivers: central obesity and metabolic syndrome, untreated obstructive sleep apnoea, poorly controlled type 2 diabetes, chronic opioid or corticosteroid use, heavy alcohol intake, sustained stress and sleep debt, thyroid disorders, raised prolactin, and prior anabolic steroid use.

Medication review: opioids, long-term corticosteroids, and some psychiatric medicines suppress the hormonal axis. Where a substitution or dose change is clinically reasonable, we coordinate it with your existing prescriber rather than layering hormone treatment on top.

Referral where indicated: sleep studies for suspected apnoea, endocrinology input for raised prolactin or pituitary findings, and diabetes or weight management input where metabolic disease is the dominant driver.

What this achieves: for many patients with secondary hypogonadism, correcting the driver restores testosterone into the normal range without lifelong replacement. Levels and symptoms are re-checked at 3 and 6 months, and TRT is reconsidered only if the picture does not improve.

For many patients with borderline-low testosterone - particularly with obesity, metabolic syndrome, or untreated sleep disorders - addressing the underlying cause restores testosterone to normal range without hormonal treatment. This is the first-line approach when criteria for TRT aren't met, and the foundation alongside TRT when they are.

Weight optimisation: For BMI above 27, structured weight loss can raise testosterone by 15-25% on average, sometimes more (see source 3 below). Medical weight loss is integrated into the hormonal treatment plan when relevant.

Sleep: Most testosterone is produced during deep sleep. Restoring 7-8 hours of consistent quality sleep, and screening for obstructive sleep apnoea where indicated, can produce meaningful improvement.

Resistance training: Regular strength training increases testosterone production and improves how the body responds to it. 2-3 sessions per week of compound movements is the evidence-based protocol.

Nutrition: Zinc and vitamin D deficiency suppress testosterone production. Adequate dietary fat (testosterone is synthesised from cholesterol) and minimal excessive alcohol are foundational.

Stress management: Chronic stress raises cortisol, which directly suppresses testosterone production. Where cortisol is elevated on testing, structured stress management is part of the protocol.

Foundational lifestyle work is included in your consultation. Additional input (dietitian, sleep medicine) is added if indicated.

TRT is a lifelong treatment for most patients. Structured monitoring is non-negotiable - it ensures the treatment continues to work, identifies side effects early, and detects any complications before they become significant.

3-month review: Total testosterone (mid-cycle for injections), free testosterone, full blood count (haematocrit), and clinical response. Dose adjusted if needed.

6-month review: Same blood panel plus lipid profile, fasting glucose/HbA1c, and PSA where indicated. DRE (digital rectal exam) at this point if not done earlier.

Annual thereafter: Comprehensive review including testosterone, haematocrit, PSA, lipids, glucose, liver function, and clinical assessment. Any new symptoms or concerns prompt additional investigation.

Your personal health concierge coordinates this monitoring schedule - booking the blood tests, sharing results, scheduling follow-up consultations, and ensuring nothing falls through the cracks. This continuity is what makes long-term hormonal care actually sustainable.

When to stop or adjust: TRT can be paused, dose-reduced, or stopped if needed. Common reasons include side effects, fertility desire, prostate concerns, or simply patient preference. Stopping is straightforward but should be done under clinical supervision.